We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

By LabMedica International staff writers
Posted on 26 Jan 2021
Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment to their long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology products, including instruments and reagents.

In 1999, Sysmex and Roche had entered into a Distributorship Sales and Service Agreement (DSS), under which Roche distributed Sysmex hematology products and provided services in overseas markets. More...
Since then, the demand for hematology testing has evolved, with greater focus on automation of manual processes and streamlining workflow, expanding the utility of hematological parameters so as to support diagnosis, monitoring and treatment across disease areas, beyond routine testing. In 2018, Roche and Sysmex entered into a non-exclusive collaboration agreement to offer Total Laboratory Solutions (TLS). This allows customers who want to purchase products for clinical chemistry, immunochemistry, and hematology testing from one vendor to do so seamlessly with Roche and Sysmex.

The GBP sees the introduction of an IT Solutions Collaboration Agreement. In the newly defined collaboration, the two companies have agreed to utilize their respective IT platforms to improve customer experience, in the short to mid-term, with a longer term ambition to use the IT systems to lead to improved clinical decision making. The GBP agreement will allow Roche and Sysmex to deliver tailored hematology solutions to new and existing customers, while having the benefits of working with a single provider. The partnership will also strive to develop a joint framework to ensure and promote connectivity through standardization of cybersecurity measures. The GBP agreement will run until the end of 2030.

“Roche is committed to supporting improvements in hematology testing, which helps patients with the diagnosis and management of blood diseases, as diverse as anemia and leukemia,” said Thomas Schinecker, CEO Roche Diagnostics. “Extending our longstanding partnership with Sysmex underscores our unique synergy and our objective to offer our customers high-quality hematology solutions to improve the testing efficiency in central laboratories in hospitals and commercial laboratories, ultimately benefiting the millions of patients living with blood disorders.”


Related Links:
Roche
Sysmex



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: A family of molecules could help diagnose and treat breast cancer (Photo courtesy of Shutterstock)

Molecular Biomarkers Pave Way for New Tests to Diagnose and Predict Breast Cancer

Despite playing essential roles in tissue development and immune protection, the contribution of proteoglycans in cancer remains poorly understood. Some proteoglycans appear to shield the body from cancer,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.